Stock Market Growth istock photo for BL | Photo Credit: innni
Trump Tariffs Impact, Indian Pharma stocks & share price updates April 3, 2024: Nifty Pharma index soared over 4% in early trade before settling 2% higher, despite equity indices recording modest losses due to US President Donald Trump’s latest tariff announcement.
Pharma stocks flout market slump on US tariffs exemption.
Pharma stocks including Sun Pharma, Lupin, Dr Reddy’s Laboratories, Gland Pharma and Cipla were in focus today.
Trump’s administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs. According to Reuters report, the US imports nearly a third of Indian pharma products sold overseas. India’s pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
Shares of Sun Pharma,Cipla and Dr Reddy’s Laboratories traded among top gainers of Nifty 50 components. All pharmaceutical stocks closed in green.
BNP Paribas analysts see a 1-2 per cent adverse impact on FY27E EBITDA assuming a baseline 10 per cent tariff cost, with Aurobindo Pharma, Zydus and Dr Reddy’s seeing the highest impact.
Pharma stocks defy market slump on US tariffs exemption, index ends 2% higher
Sun Pharmaceuticals led the gainers of Nifty 50 components to end 3.41 per cent positive at ₹1,772. The stock soared 6 per cent from the previous close to hit a high of ₹1,812.70.
Cipla shares followed with 3.28 per cent increase to end at ₹1,500, after hitting a high of ₹1,523.30.
Dr Reddy’s Laboratories stock jumped 7 per cent before settling flat at ₹1,151.80.
All pharma stocks ended in green, Ipca Laboratories led with 4.59 per cent surge, Lupin followed with 4.19 per cent increase, Natco Pharma with a 4.06 per cent uptick and Gland Pharma with 1.23 per cent gain.
Aurobindo Pharma rose 1.51 per cent to end at ₹1,175.35 and Divi’s Laboratories were up 1.73 per cent to ₹5,764.
Check what brokerages and market experts say | Read here
Pharma stocks flout market slump on US tariffs exemption
Pharma stocks surge after US exempts products from tariffs, Nifty Pharma and healthcare indices show positive gains.
- 15:54 | April 3, 2025
Trump’s tariffs: Govt carefully examining implications of US reciprocal tariffs on India - PTI
The Department of Commerce is carefully examining the implications of the US reciprocal tariffs on India and is engaged with all stakeholders, including domestic industry and exporters to seek their feedback on the issue, an official statement said on Thursday.
The commerce ministry said that it is also studying the opportunities that may arise due to this new development in the US trade policy.
US President Donald Trump has announced the imposition of additional ad-valorem duties ranging from 10 per cent to 50 per cent on imports from all trading partners.
The baseline duty of 10 per cent will be effective from April 5 and the 27 per cent from April 9. Certain sectors are exempted from these duties include pharma, semiconductors and energy products.
“The Department of Commerce is carefully examining the implications of the various measures/ announcements made by the President of the USA,” it said.
It also said that discussions are ongoing between Indian and US trade teams for the expeditious conclusion of a mutually beneficial, multi-sectoral Bilateral Trade Agreement (BTA).
The BTA will cover a wide range of issues of mutual interest including deepening of supply chain integration.
The ongoing talks are focused on enabling both nations to grow trade, investments and technology transfers.
“We remain in touch with the Trump Administration on these issues and expect to take them forward in the coming days,” it said.
It added that India values its Comprehensive Global Strategic Partnership with the United States and is committed to working closely with the US for the benefit of the people of both the countries.
- PTI
- 15:46 | April 3, 2025
Nifty pharma index ends 2.25% positive at 21,423.55.
- 15:40 | April 3, 2025
Pharma stocks live: All pharmaceutical stocks end in green
- 15:39 | April 3, 2025
Stock market live updates: Indices end with modest losses
Indices closed with modest losses. Sensex ended 322.08 pts or 0.42% lower at 76,295.36, after opening at 75,811.86. Nifty 50 declined 82.25 pts or 0.35% to 23,250.10. Nifty IT index fell over 4%, while Pharma was up 2%.
- 15:15 | April 3, 2025
Lupin share price live: Shares soar 4%
Shares of Lupin traded 4.22% higher on the NSE at ₹2,094.50 as at 3.12 pm. The stock hit an intraday high of ₹2,150, 7% higher from the previous close of ₹2,009.70.
The stock has benefited from the sectoral uptrend.
On April 2, Lupin announced that its wholly owned subsidiary Lupin Healthcare (UK) entered into a definitive agreement and acquired the entire share capital of Renascience Pharma Limited, United Kingdom.
- 15:05 | April 3, 2025
Stock market live updates: Sun Pharma and Cipla among top gainers of Nifty 50
Top gainers on the NSE:
Power Grid (+3.91%), Sun Pharma (+3.18%), Cipla (+3%), UltraTech (+2.98%), Shriram Finance (+2.39%)
Top losers:
TCS (-3.94%), Tech Mahindra (-3.79%), HCL Tech (-3.77%), Infosys (-3.58%), ONGC (-3.11%)
- 15:02 | April 3, 2025
Stock market live updates: 2,687 stocks advanced, 1,236 declined on the BSE
Stocks advanced on BSE at 3 pm on April 3, 2025, were 2,687 against 1,236 stocks that declined, and 141 remained unchanged. Total stocks traded were 4,064. The number of stocks that recorded a 52-week high was 60, and those that hit a 52-week low was 49. A total of 444 stocks traded in the upper circuit, and 140 in the lower circuit.
- 14:47 | April 3, 2025
Pharma stocks live today: Expert view | Anuj Sethi, Senior Director, Crisil Ratings on US tariff impact on pharmaceuticals
No tariffs imposed by US Administration on pharmaceuticals
The US Administration has exempted pharmaceuticals from reciprocal tariffs, given its focus on enhancing availability of affordable medical care of the US citizens. To be sure, India exported ~ USD 8 billion of pharma products to USA in fiscal 2024, its largest export destination, and supplies ~40% of generics consumed in the USA and this move by the US Administration will help sustain exports. India has more than 650 manufacturing facilities approved by the US Food and Drugs Administration (USFDA), the second-highest number outside the US. They account for a quarter of all such certified facilities outside the US.
The possibility of tariffs being imposed by the US Administration on pharmaceuticals at a later stage cannot, however, be ruled out. That said, several potentially mitigating factors - ongoing drug shortages in the US, the higher cost of domestic pharmaceutical production in USA, and declining profitability of US pharma firms – are expected to be taken into consideration before any such imposition.
- Anuj Sethi, Senior Director, Crisil Ratings
- 14:27 | April 3, 2025
Pharma stocks live: India’s pharmaceutical products may be subject to duties in future actions under US Trade Expansion Act of 1962: Report - ANI
The recent imposition of a 27 per cent reciprocal tariff on Indian exports by the United States, while exempting the pharmaceutical sector, has raised concerns about potential future trade restrictions on drug exports.
According to a report by HDFC Securities, pharmaceutical products could become subject to duties under the Trade Expansion Act of 1962 in future trade actions.
The Trade Expansion Act of 1962 grants the U.S. President the authority to modify international trade tariffs, including imposing new duties on imports. While Indian pharmaceutical exports remain unaffected in the first round of tariffs, the report warned that this relief may be temporary.
It said, “The key concerns around price increase for the generic medicines in the US, drug shortages, rationalization from low-margin products, and supply chain disruption are temporarily alleviated, for now. However, pharmaceutical products may become subject to duties under future actions pursuant to the Trade Expansion Act of 1962”.
Indian generic drug manufacturers play a significant role in the U.S. healthcare system, supplying nearly 40 percent of the generic drugs imported into the country. In FY24, Indian pharmaceutical exports to the U.S. were valued at approximately USD 8 billion, with the industry witnessing an 8 percent compound annual growth rate (CAGR) over FY15- 24.
Despite being exempted from tariffs, Indian pharmaceutical stocks have already reacted to the potential risk of future levies. The Indian pharma index has declined by nearly 10 per cent in the past three months. Analysts believe that a continued exemption would be beneficial for the sector, ensuring steady exports to the U.S.
However, if the U.S. imposes tariffs on Indian pharmaceutical products in the future, both countries could face adverse consequences. The U.S. relies on low-cost Indian generics to control healthcare costs. Any additional tariffs on pharmaceutical imports could drive up drug prices in the U.S., leading to higher healthcare inflation.
Meanwhile, Indian manufacturers, already operating on thin margins in the generics market, may struggle to absorb these additional costs without passing them on to consumers or insurers. This could result in drug shortages and further margin compression for Indian pharma firms.
The Indian pharmaceutical industry has long been a crucial part of the U.S. healthcare system by providing cost-effective generic medicines. Any future tariffs could disrupt this balance, impacting both the affordability of medicines in the U.S. and the profitability of Indian pharmaceutical companies.
ANI
- 14:00 | April 3, 2025
Pharma stocks live today: Ipca, Lupin, Sun Pharma lead gainers
Nifty Pharma traded 2.29% positive as at 1.59 pm at 21,433.
Major gainers:
- Ipca Laboratories (+4.52%)
- Lupin (+3.87%)
- Sun Pharma (+3.23%)
- Cipla (+3.18%)
- Natco Pharma (+2.82%)
- 13:34 | April 3, 2025
Pharma stocks live: Medicamen Biotech stock jumps 9%
Medicamen Biotech has signed a contract for CDMO with XGX pharma, European company where Medicamen will develop 6 products and will do manufacturing of these products for European company.
Shares jump 9.15% on the NSE to ₹530.
- 13:26 | April 3, 2025
Trump’s tariffs drag market; IT majors TCS, Wipro, Tech Mahindra, Infosys, Coforge plunge
NSE BSE Top gainers, losers today: Sensex, Nifty trade lower as Trump’s tariffs weigh, IT majors TCS, Wipro, Tech Mahindra, Infosys, Coforge plunge
Sensex, Nifty continue to trade lower as Trump’s tariffs weigh high. IT stocks plunge.
- 13:22 | April 3, 2025
Pharma stocks live: Brokerage view | BNP Paribas
Assuming a baseline 10% tariff cost, in our bear case scenario (40% cost absorption), we see a 1-2% adverse impact on our FY27E EBITDA, with ARBP, ZYDUSLIF and DRRD seeing the highest impact and DIVI’s is likely to be the least impacted.
BNP Paribas analysts
- 13:09 | April 3, 2025
Sun Pharma share price live: Shares up nearly 4%
Shares of Sun Pharma rose 3.52% on the NSE to ₹1,774 as at 1.08 pm.
- 12:27 | April 3, 2025
Shilpa Medicare stock live updates: Stock soars 5%
Shilpa Medicare’s marketing partner, Amneal Pharmaceuticals, has launched BORUZU, (Bortezomib for injection3.5mg/1.4ml), a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration.
Stock surged 5.08% on the NSE to ₹681.
- 12:14 | April 3, 2025
Cipla share price live: Shares trade in green
Shares of Cipla Ltd traded3.25% positive on the NES at ₹1,499.55 as at 12.13 pm, after hitting an intraday high of 1,523.30.
The stock opened 2% higher from previous close of ₹1,452.35.
- 11:39 | April 3, 2025
US tariffs impact on pharma sector live: Expert opinion | Bhavin Mukund Mehta, Vice-Chairman of Pharmexcil and Whole-Time Director of Kilitch Drugs Ltd, sees pharmaceutical sector as clear winner.
“As India evaluates the impact of reduced tariffs, we recognise the pharmaceutical sector as the clear winner. With India importing $800 million worth of pharmaceutical products from the U.S. and exporting $8.7 billion, the strong trade ties between the two countries create a powerful win-win scenario. This shift drives significant cost savings on life-saving medicines and also positions Indian exporters to gain a competitive edge over their Asian counterparts, further strengthening India’s leadership in the global pharmaceutical market.”
- Mr. Bhavin Mukund Mehta, Vice-Chairman of Pharmexcil and Whole-Time Director of Kilitch Drugs Ltd.
- 11:17 | April 3, 2025
Gland Pharma stock live: Shares rise 3%
Gland Pharma receives approval for Acetaminophen Injection
Stock traded 3.45% positive on the NSE at ₹1,588.
- 11:15 | April 3, 2025
US tariffs: Pharma industry needs long-term measures to reduce US dependence, says Pharmexcil ex-DG Uday Bhaskar
Even though pharma imports from India into the US have been exempted from the levy of reciprocal tariffs by the US administration, caution and long-term measures are the need of the hour, according to R Uday Bhaskar, former director general of Pharmaceutical Exports Promotion Council (Pharmexcil).
- 11:10 | April 3, 2025
Pharma stocks live today: Top gainers
Top gainers of Nifty pharma stocks as at 11 am outlook
Lupin (+4.50%), Ipca Lab (+4.43%), Sun Pharma (+4.38%), Gland Pharma (+3.92%)
- 10:43 | April 3, 2025
US Tariffs impact on pharma sector | Pharmexcil
Pharma: Even though pharma imports from India into the US have been exempted from the levy of reciprocal tariffs by the US administration, caution and long-term measures are need of the hour, according to R Uday Bhaskar, former director general of Pharmaceutical Exports Promotion Council (Pharmexcil).
- 10:41 | April 3, 2025
Pharma stocks flout market slump on US tariffs exemption
Market and industry experts see this as positive sign for Indian pharma companies.
Which stocks will benefit? Read here
Pharma stocks flout market slump on US tariffs exemption
Pharma stocks surge after US exempts products from tariffs, Nifty Pharma and healthcare indices show positive gains.
- 10:20 | April 3, 2025
Pharma stocks today live: Trump tariffs impact | Brokerage recommendations
Citi on Pharma stocks: Pharma sector has been excluded from tariffs announced by Trump administration. Key stocks with higher revenue mix from the US are Aurobindo (48%), Zydus (47%) and Dr Reddys (46%) (Positive)
CLSA on Pharma stocks: Pharma being exempt from US tariffs is a positive sign for Indian cos. Stocks with higher revenue mix are Aurobindo, Zydus & DrReddy’s (Positive)
- 09:59 | April 3, 2025
Nifty Pharma stocks today: Shares in green | Top gainers
Gland Pharma (+7.20%)
Lupin (+4.59%)
Ipca Lab (+4.52%)
Aurobindo Pharma (+4.28%)
Sun Pharma (+4.27%)
Natco Pharma (+3.79%)
- 09:55 | April 3, 2025
Pharma stocks live: Indian pharma stocks defy market slump on US tariffs exemption - Reuters
Shares of Indian drugmakers surged 4% on Thursday, in contrast to the drop in the broader stock market, after U.S. President Donald Trump’s administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs.
The pharma sub-index was the only one among the 13 major sectors that was trading higher. The benchmark Nifty 50 was down 0.74%.
Trump imposed a 26% reciprocal tariff on Indian imports as part of his wider plan to impose a 10% baseline tariff on all imports from April 5, but the duties do not apply to certain goods, including pharmaceuticals.
The U.S. imports nearly a third of Indian pharma products sold overseas. India’s pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
On the day, Dr Reddy’s climbed 6% and was the top gainer on the benchmark Nifty 50 index. Gland Pharma surged 12% and was the top gainer among pharma stocks.
Cipla and Sun Pharma rose 4% each.
Reuters
- 09:54 | April 3, 2025
Nifty pharma stocks live: Sun Pharma, Dr Reddy’s Laboratories, Cipla lead gainers of Nifty 50 components
Top gainers on the NSE as at 9.33 am:
Sun Pharma (+5.53%), Dr Reddy’s (+5%), Cipla (+4.09%)
- 09:53 | April 3, 2025
US tariffs: Indian pharma heaves a sigh of relief, for now
Indian drugmakers are heaving a sigh of relief, for now, as United States President Donald Trump unveiled his “reciprocal tariff” plans.
“Pharmaceuticals have been exempted from tariffs. The decision underscores the critical role of cost-effective, life-saving generic medicines in public health, economic stability, and national security,” the Indian Pharmaceutical Alliance said on Thursday, as the full implications of the tariff plan are still being digested.
- 09:52 | April 3, 2025
Trump’s tariff impact: Pharma stocks in focus today.
Nifty Pharma index soared over 4% in early trade, despite equity indices opening lower due to US President Donald Trump’s latest tariff announcement.
Trump’s administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs. According to Reuters report, the US imports nearly a third of Indian pharma products sold overseas. India’s pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
Shares of Sun Pharma, Dr Reddy’s Laboratories and Cipla traded among top gainers of Nifty 50 components. All pharmaceutical stocks traded in green.
Published on April 3, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.